Cardiac allograft vasculopathy laboratory findings

Cardiac allograft vasculopathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Differentiating Cardiac allograft vasculopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Coronary Angiography
Intravascular Ultrasound
Optical Coherence Tomography
CT
MRI
Echocardiography
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cardiac allograft vasculopathy laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiac allograft vasculopathy laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiac allograft vasculopathy laboratory findings
CDC on Cardiac allograft vasculopathy laboratory findings
Cardiac allograft vasculopathy laboratory findings in the news
Blogs on Cardiac allograft vasculopathy laboratory findings
Directions to Hospitals Treating Cardiac allograft vasculopathy
Risk calculators and risk factors for Cardiac allograft vasculopathy laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]

Overview

Multiple biomarkers such as C-reactive protein, von Willebrand factor and NT-pro-BNP are used to predict all cause mortality in patients with CAV. Elevated levels of each of these biomarkers signify increased risk of developing CAV. Further research is warranted to help identify the role of biomarkers in diagnosing and predicting CAV.